Brief: HBM Holdings Announces License And Equity Partnership Deal With Solstice Oncology For HBM4003
23/02/2026 02:09
Feb 23 (Reuters) - Hbm Holdings Ltd 2142.HK: LICENSE AGREEMENT AND EQUITY PARTNERSHIP AGREEMENT WITH SOLSTICE ONCOLOGY FOR HBM4003 CO TO GET UPFRONT CONSIDERATION VALUED AT OVER US$105 MILLION ELIGIBLE TO RECEIVE ADDITIONAL DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS OF UP TO US$1.1 BILLION TO GRANT SOLSTICE ONCOLOGY AN EXCLUSIVE LICENSE TO DEVELOP AND OTHERWISE COMMERCIALIZE HBM4003 OUTSIDE GREATER CHINA Further company coverage: 2142.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study